Ocular toxicity and mitigation strategies for antibody drug conjugates in gynecologic oncology
Debra L. Richardson
Abstract
Recently, two antibody drug conjugates were FDA approved for the treatment of recurrent gynecologic malignancies. Both of these new agents are associated with ocular toxicity. Ocular toxicity can be prevented and mitigated by utilizing recommended eye care strategies.
Topics & Concepts
MedicineToxicityGynecologic oncologyDrugAntibody-drug conjugateDrug toxicityOncologyAntibodyPharmacologyInternal medicineMonoclonal antibodyImmunologyAdvanced Breast Cancer TherapiesCancer Treatment and PharmacologyHER2/EGFR in Cancer Research